$36.90
0.05% day before yesterday
NYSE, Sep 06, 10:10 pm CET
ISIN
VGG111961055
Symbol
BHVN
Sector
Industry

Biohaven Pharmaceutical Holding Company Ltd. Stock price

$36.90
+1.18 3.30% 1M
-21.23 36.52% 6M
-5.90 13.79% YTD
+18.50 100.54% 1Y
-99.40 72.93% 3Y
-4.59 11.06% 5Y
+19.40 110.86% 10Y
NYSE, Closing price Fri, Sep 06 2024
-0.02 0.05%
ISIN
VGG111961055
Symbol
BHVN
Sector
Industry

Key metrics

Market capitalization $3.49b
Enterprise Value $3.08b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 8.88
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-781.27m
Free Cash Flow (TTM) Free Cash Flow $-485.24m
Cash position $437.10m
EPS (TTM) EPS $-9.16
P/E forward negative
Short interest 12.33%
Show more

Is Biohaven Pharmaceutical Holding Company Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Biohaven Pharmaceutical Holding Company Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:

12x Buy
100%

Analyst Opinions

12 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:

Buy
100%

Financial data from Biohaven Pharmaceutical Holding Company Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 3.72 3.72
62% 62%
-
-3.72 -3.72
62% 62%
-
- Selling and Administrative Expenses 73 73
37% 37%
-
- Research and Development Expense 701 701
111% 111%
-
-778 -778
73% 73%
-
- Depreciation and Amortization 3.72 3.72
62% 62%
-
EBIT (Operating Income) EBIT -781 -781
73% 73%
-
Net Profit -747 -747
73% 73%
-

In millions USD.

Don't miss a Thing! We will send you all news about Biohaven Pharmaceutical Holding Company Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biohaven Pharmaceutical Holding Company Ltd. Stock News

Neutral
PRNewsWire
about one month ago
Cash, cash equivalents, marketable securities and restricted cash totaled approximately $440 million on June 30, 2024 Biohaven's Molecular Degrader of Extracellular Proteins (MoDE™) platform advancing multiple new targets and reported positive interim data from its lead investigational drug in an ongoing Phase 1 study of BHV-1300: The Company reported dose-dependent and rapid IgG reductions in ...
Positive
Seeking Alpha
about one month ago
Results from phase 3 RESILIENT study, using taldefgrobep alfa for the treatment of patients with spinal muscular atrophy, expected in the 2nd half of 2024. The global spinal muscular atrophy treatment market is projected to reach $8.4 billion by 2032. Preclinical model testing showed that myostatin inhibitor taldefgrobep alfa + GLP-1 inhibitor was able to show greater reductions in body weight ...
Positive
InvestorPlace
2 months ago
Healthcare stocks to buy have been off to the races recently — especially the ones in the weight-loss drug market. Indeed, the market is huge and could entail considerable growth for many years into the future.
More Biohaven Pharmaceutical Holding Company Ltd. News

Company Profile

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.

Head office Virgin Islands, British
CEO Vladimir Coric
Employees 239
Founded 2022
Website www.biohaven.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today